ALAMAR BIOSCIENCES INC (ALMR)
Health Care · Life Science Tools & Services · NASDAQ
Alamar Biosciences is a proteomics company providing a high-sensitivity platform for precise protein biomarker detection and analysis to drive medical research and future diagnostics.
What ALAMAR BIOSCIENCES INC does
Alamar Biosciences is a commercial-stage proteomics company that provides an integrated platform for the detection and analysis of protein biomarkers. Its proprietary NULISA technology enables ultra-sensitive detection of proteins in biological fluids like blood, supporting applications ranging from discovery and translational research to future diagnostics. The company's primary offering, the ARGO HT System, is supported by a suite of proprietary consumables and analytical software.
Themes: proteomics, biomarker discovery, precision medicine, in vitro diagnostics (IVD), life science tools
Fundamentals
- Price$34.24 as of 2026-08-21 close
- Market cap$2.4B as of 2026-08-21
- P/En/a negative earnings
- Net margin-40.2% as of 2026-08-24
- Gross margin+56.2% as of 2026-08-24
- ROE-39.2% as of 2026-08-24
- Debt / equity1.32 as of 2026-08-24
- Beta-0.19 as of 2026-08-24
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How ALMR compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ALAMAR BIOSCIENCES INC looks technically
ALAMAR BIOSCIENCES INC (ALMR): a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 9 trading days ago.
Trend
7
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $26.84 | $26.84 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with buyers in control | 42.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30) | 63.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($26.22 to $38.54) — its "stochastic" reading is 65 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 65.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $38.54 | $38.54 |
|---|---|---|
| From the 52-week high | it is 11.2% below its 52-week high (its highest price of the past year) | -11.2% |
| Above the 52-week low | it is 77.7% above its 52-week low (its lowest price of the past year) | +77.7% |
| Below the 52-week high | it is 11.2% below its highest point of the past year | 11.2% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day high about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $38.54 (set on 2026-08-11) | $38.54 |
| Given back of the 52-week move | not available for this company yet | n/a |
| From the all-time high | it is 11.2% below its all-time high | -11.2% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $19.27 (set on 2026-06-09) | $19.27 |
| Above the all-time low | it is 77.7% above its all-time low | +77.7% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 97% of the past ~6 months) | 97th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.49 between its high and its low — about 7.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.49 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $21.80 and $37.82 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $21.80 – $29.81 – $37.82 |
| Typical daily range (% of price) | its price moves about 7.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.3% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.70× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 5.0% since the prior reading | +5.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Open gap | it gapped 2.6% above the previous close 2 sessions ago and has not traded back through the level it left behind at 32.96 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.5% |
| Gap filled | a 2.7% gap up opened on 2026-08-14 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 5 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -3.66% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 33.8 percentage points (the stock gained 36.1% while the market gained 2.3%) | +33.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 52.5 percentage points (the stock gained 55.6% while the market gained 3.1%) | +52.5% |
| vs market, 6 months | not available for this company yet | n/a |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 3 of the 6 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 6 |
|---|---|---|
| Bearish technical signals | 0 of the 6 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 6 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 34% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.6% of the share price. | +33.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 34% above the average price paid since 2026-04-17, so the typical buyer over that stretch is showing a gain. That average is $25.64 — a volume-weighted average of daily closes over 78 sessions, not a true tick-by-tick VWAP. | +33.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-10 (its 8-K), so the typical buyer over that stretch is roughly break-even. That average is $34.38 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | -0.4% |
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: in a strong, established uptrend (ADX) · Analyst price target recently RAISED · Most volatile (6%+ typical daily range) · Trading above the Ichimoku cloud | Learn: adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.60 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$33.40 range $31.00 – $35.00; median $34.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ALMR
- Consensus EPS estimate-$0.3223 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on research use only (RUO) market with future IVD regulatory hurdles","History of operating losses and potential need for additional capital","Highly competitive and rapidly evolving proteomics technology landscape"]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days2 buys ($8M) · 0 sells — 2 buying insiders
Most recent open-market transaction: 2026-04-20. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ALMR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
ALMR had 2,430,004 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ALMR had 3.50% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.32 days to cover at the same settlement.
- Reported short interest (shares) 2,430,004
- Short interest (% of shares outstanding) 3.50%
- Prior settlement (shares) 2,245,722
- Reported change 8.21%
- Days to cover (reported) 11.32
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Olink (acquired by Thermo Fisher Scientific)
- SomaLogic (acquired by Standard BioTools)
- Quanterix (QTRX)
- Seer (SEER)
- Bio-Rad Laboratories (BIO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ALMR vs…
ALAMAR BIOSCIENCES INC is found in…
Frequently asked questions
What does ALAMAR BIOSCIENCES INC (ALMR) do?
Alamar Biosciences is a commercial-stage proteomics company that provides an integrated platform for the detection and analysis of protein biomarkers. Its proprietary NULISA technology enables ultra-sensitive detection of proteins in biological fluids like blood, supporting applications ranging from discovery and translational research to future diagnostics. The company's primary offering, the ARGO HT System, is supported by a suite of proprietary consumables and analytical software.
What sector is ALAMAR BIOSCIENCES INC (ALMR) in?
ALAMAR BIOSCIENCES INC (ALMR) is classified in the Health Care sector. Its industry is Life Science Tools & Services. It trades on NASDAQ.
Who are ALAMAR BIOSCIENCES INC's (ALMR) competitors?
Notable peers of ALAMAR BIOSCIENCES INC (ALMR) include Olink (acquired by Thermo Fisher Scientific), SomaLogic (acquired by Standard BioTools), Quanterix, Seer and Bio-Rad Laboratories. This peer set is informational only — not financial advice.
Is ALAMAR BIOSCIENCES INC (ALMR) overbought or oversold right now?
ALAMAR BIOSCIENCES INC (ALMR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 64, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ALMR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.